Evaluate’s Orphan Drug Report 2022
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights […]
Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights […]
R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any. However, Ben […]
If you were a drug manufacturer, you naturally would want to focus your research on more common, highly prevalent diseases. If there are more patients […]
There are currently an estimated 300 million people living with one or more Rare Diseases across the world. There are over 7,000 Rare Diseases that […]
That is a title of a new white paper from FTI Consulting and Alexion. The key findings from the article are: HTA practices are designed […]
Last month, the Government Accountability Office released a report on the cost of rare disease. The report is interesting, and especially interesting is Appendix 1 […]
Far more common than initially thought, rare disease treatments remain far too scarce. The answer to the problem, of course, lays in making medical research […]
This is the question posed by a recent article by Lopata et al. (2021). The authors surveyed 26 payers (e.g., leaders of national, regional, local, […]
Rare diseases–also go by the name Orphan diseases–are the conditions that do not affect many individuals out there in one particular geographic area. Going deeper […]
How is a Rare disease defined? Well, it depends on the geography in question, since there is no universal definition, even so, the definition revolves […]
New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe. Rare diseases drugs have always […]
Copyright © 2024 | WordPress Theme by MH Themes